Susan E Krown

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. pmc Rapamycin with antiretroviral therapy in AIDS-associated Kaposi sarcoma: an AIDS Malignancy Consortium study
    Susan E Krown
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Acquir Immune Defic Syndr 59:447-54. 2012
  2. pmc Treatment strategies for Kaposi sarcoma in sub-Saharan Africa: challenges and opportunities
    Susan E Krown
    AIDS Malignancy Consortium, c o The EMMES Corporation, Rockville, Maryland, USA
    Curr Opin Oncol 23:463-8. 2011
  3. doi Pilot study of oral valganciclovir therapy in patients with classic Kaposi sarcoma
    Susan E Krown
    Melanoma and Sarcoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Infect Dis 203:1082-6. 2011
  4. pmc AIDS-associated Kaposi's sarcoma: is there still a role for interferon alfa?
    Susan E Krown
    Melanoma Sarcoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Cytokine Growth Factor Rev 18:395-402. 2007
  5. ncbi Interferon-alpha2b with protease inhibitor-based antiretroviral therapy in patients with AIDS-associated Kaposi sarcoma: an AIDS malignancy consortium phase I trial
    Susan E Krown
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Acquir Immune Defic Syndr 41:149-53. 2006
  6. ncbi Interferon-alpha: evolving therapy for AIDS-associated Kaposi's sarcoma
    S E Krown
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Interferon Cytokine Res 18:209-14. 1998
  7. ncbi Therapy of AIDS-associated Kaposi's sarcoma: targeting pathogenetic mechanisms
    Susan E Krown
    Clinical Immunology Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Hematol Oncol Clin North Am 17:763-83. 2003
  8. ncbi Efficacy of low-dose interferon with antiretroviral therapy in Kaposi's sarcoma: a randomized phase II AIDS clinical trials group study
    Susan E Krown
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Interferon Cytokine Res 22:295-303. 2002
  9. ncbi Management of Kaposi sarcoma: the role of interferon and thalidomide
    S E Krown
    Clinical Immunology Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Curr Opin Oncol 13:374-81. 2001
  10. ncbi Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma
    Wen Jen Hwu
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 106:2445-51. 2006

Research Grants

Detail Information

Publications40

  1. pmc Rapamycin with antiretroviral therapy in AIDS-associated Kaposi sarcoma: an AIDS Malignancy Consortium study
    Susan E Krown
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Acquir Immune Defic Syndr 59:447-54. 2012
    ....
  2. pmc Treatment strategies for Kaposi sarcoma in sub-Saharan Africa: challenges and opportunities
    Susan E Krown
    AIDS Malignancy Consortium, c o The EMMES Corporation, Rockville, Maryland, USA
    Curr Opin Oncol 23:463-8. 2011
    ....
  3. doi Pilot study of oral valganciclovir therapy in patients with classic Kaposi sarcoma
    Susan E Krown
    Melanoma and Sarcoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Infect Dis 203:1082-6. 2011
    ..Although valganciclovir was not active against KS in this setting, other appropriately targeted anti-herpesviral strategies may prove to be more effective...
  4. pmc AIDS-associated Kaposi's sarcoma: is there still a role for interferon alfa?
    Susan E Krown
    Melanoma Sarcoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Cytokine Growth Factor Rev 18:395-402. 2007
    ....
  5. ncbi Interferon-alpha2b with protease inhibitor-based antiretroviral therapy in patients with AIDS-associated Kaposi sarcoma: an AIDS malignancy consortium phase I trial
    Susan E Krown
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Acquir Immune Defic Syndr 41:149-53. 2006
    ..This study establishes a safe dose of IFN that can be used with HAART and, potentially, with other inhibitors of KS in future clinical trials...
  6. ncbi Interferon-alpha: evolving therapy for AIDS-associated Kaposi's sarcoma
    S E Krown
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Interferon Cytokine Res 18:209-14. 1998
    ....
  7. ncbi Therapy of AIDS-associated Kaposi's sarcoma: targeting pathogenetic mechanisms
    Susan E Krown
    Clinical Immunology Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Hematol Oncol Clin North Am 17:763-83. 2003
    ....
  8. ncbi Efficacy of low-dose interferon with antiretroviral therapy in Kaposi's sarcoma: a randomized phase II AIDS clinical trials group study
    Susan E Krown
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Interferon Cytokine Res 22:295-303. 2002
    ..These findings justify the use of lower, well-tolerated IFN doses for treatment of KS with currently used antiretroviral regimens...
  9. ncbi Management of Kaposi sarcoma: the role of interferon and thalidomide
    S E Krown
    Clinical Immunology Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Curr Opin Oncol 13:374-81. 2001
    ..Studies are ongoing to explore the optimal way to use these agents and their mechanisms of action...
  10. ncbi Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma
    Wen Jen Hwu
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 106:2445-51. 2006
    ..Therefore, the efficacy and safety of temozolomide in combination with pegylated IFN-alpha-2b in patients with metastatic melanoma without brain metastases was investigated...
  11. ncbi Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study
    Wen Jen Hwu
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 103:2590-7. 2005
    ..The current Phase II study examined the efficacy and safety of this combination in chemotherapy-naive patients with brain metastases...
  12. doi Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma
    Miguel Angel Perales
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Mol Ther 16:2022-9. 2008
    ..Responding T cells had an effector memory cell phenotype. Polyfunctional T cells were also demonstrated. At a median of 31 months follow-up, median survival has not been reached. Human GM-CSF DNA was found to be a safe adjuvant...
  13. ncbi A phase II trial comparing five dose levels of BEC2 anti-idiotypic monoclonal antibody vaccine that mimics GD3 ganglioside
    Paul B Chapman
    Clinical Immunology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Vaccine 22:2904-9. 2004
    ..5 mg dose used in previous BEC2 trials. Prolonged booster immunizations did not induce or maintain antibody responses...
  14. ncbi Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma
    Wen Jen Hwu
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 21:3351-6. 2003
    ..To further investigate the efficacy and safety of temozolomide plus thalidomide in patients with metastatic melanoma without brain metastases...
  15. pmc Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy
    Mary Cianfrocca
    Department of Medicine, Northwestern University, Chicago, Illinois 60611, USA
    Cancer 116:3969-77. 2010
    ..A randomized trial comparing the efficacy and toxicity of paclitaxel and PLD was performed, and the effects of therapy on symptom palliation and quality of life were determined...
  16. ncbi Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102)
    Susan E Krown
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 107:1883-90. 2006
    ..To confirm these observations the combination was tested in a multicenter Phase II trial in patients with melanoma brain metastases...
  17. ncbi Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications
    Y B Su
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Clin Oncol 22:610-6. 2004
    ..Using an extended dosing schedule, we noted a high incidence of lymphopenia and occasional opportunistic infections (OIs). Here we report our retrospective experience in the first 97 patients...
  18. doi Phase 1/2 trial of BMS-275291 in patients with human immunodeficiency virus-related Kaposi sarcoma: a multicenter trial of the AIDS Malignancy Consortium
    Brett T Brinker
    Division of Hematology Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University and the Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA
    Cancer 112:1083-8. 2008
    ....
  19. pmc Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma
    Jianda Yuan
    Ludwig Center for Cancer Immunotherapy, Immunology Program, Sloan Kettering Institute, New York, NY, USA
    Cancer Immun 9:5. 2009
    ..One patient had an increase in CD8+ IFN-gamma+ cells. This xenogeneic immunization strategy was safe and associated with minimal toxicity. There was also evidence of immune response...
  20. ncbi Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21
    Govind Ragupathi
    Laboratory of Tumor Vaccinology, Clinic Immunology Service, Department of Medicine Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 9:5214-20. 2003
    ..However, vaccination of patients with GD2-KLH has previously failed to induce a consistent relevant antibody response. We test here whether the use of GD2 lactone-KLH can overcome the low immunogenicity of GD2-KLH...
  21. ncbi Safety and immunogenicity of tyrosinase DNA vaccines in patients with melanoma
    Jedd D Wolchok
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Mol Ther 15:2044-50. 2007
    ..Mouse and human TYR DNA vaccines were found safe and induced CD8(+) T-cell responses in 7 of 18 patients. T cells recognizing a native TYR peptide had a phenotype consistent with that of effector memory cells...
  22. ncbi Phase I trial of high dose paracetamol and carmustine in patients with metastatic melanoma
    Jedd D Wolchok
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Melanoma Res 13:189-96. 2003
    ..The observation of two partial responses has led to a phase II study to evaluate treatment with high dose paracetamol alone or in combination with BCNU...
  23. pmc Time for oncologists to opt in for routine opt-out HIV testing?
    Elizabeth Y Chiao
    Department of Medicine, Baylor College of Medicine, and Health Services Research and Development, Department of Veterans Affairs Medical Center, Houston, Texas 77030, USA
    JAMA 304:334-9. 2010
    ..In addition, evidence is discussed for the potential of opt-out HIV testing to improve clinical outcomes by facilitating appropriate HIV management during cancer treatment for individuals who are found to be HIV positive...
  24. ncbi Infrared coagulator treatment of high-grade anal dysplasia in HIV-infected individuals: an AIDS malignancy consortium pilot study
    Elizabeth A Stier
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Acquir Immune Defic Syndr 47:56-61. 2008
    ..To evaluate prospectively the safety of the infrared coagulator (IRC) as a treatment for anal high-grade squamous intraepithelial lesions (HSILs) in HIV-infected individuals and to seek preliminary evidence for efficacy...
  25. ncbi A population-based analysis of temporal trends in the incidence of squamous anal canal cancer in relation to the HIV epidemic
    Elizabeth Y Chiao
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Acquir Immune Defic Syndr 40:451-5. 2005
    ..The incidence of SCCA has particularly increased among men and those between 30 and 54 years of age since the introduction of HAART...
  26. ncbi Highly active antiretroviral therapy in AIDS-associated Kaposi's sarcoma: implications for the design of therapeutic trials in patients with advanced, symptomatic Kaposi's sarcoma
    Susan E Krown
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 22:399-402. 2004
  27. pmc Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma
    David B Solit
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 14:8302-7. 2008
    ..We conducted a phase II trial using the hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) in melanoma patients. The primary end points were clinical responses and whether treatment inhibited MAPK pathway activity...
  28. ncbi Update on non-acquired immunodeficiency syndrome-defining malignancies
    Elizabeth Y Chiao
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Curr Opin Oncol 15:389-97. 2003
    ..We review the most recent data regarding clinical presentation, pathology, and treatment outcomes for these non-AIDS-defining malignancies...
  29. ncbi Use of liposomal anthracyclines in Kaposi's sarcoma
    Susan E Krown
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Semin Oncol 31:36-52. 2004
    ..Health-related quality of life was improved in several domains in patients treated with PLD or DNX compared with ABV...
  30. ncbi Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial
    Wen Jen Hwu
    Departments of Medicine, Epidemiology and Biostatistics, and Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 20:2610-5. 2002
    ..To establish a safe and tolerated regimen of an oral cytotoxic agent, temozolomide, and a cytostatic agent, thalidomide, in patients with unresectable stage III or IV malignant melanoma...
  31. ncbi Defining adequate surgery for primary melanoma
    Susan E Krown
    N Engl J Med 350:823-5. 2004
  32. ncbi Phase II evaluation of low-dose oral etoposide for the treatment of relapsed or progressive AIDS-related Kaposi's sarcoma: an AIDS Clinical Trials Group clinical study
    Scott R Evans
    Center for Biostatistics in AIDS Research, Department of Biostatistics, Harvard School of Public Health, Boston, MA, USA
    J Clin Oncol 20:3236-41. 2002
    ..To identify new interventions for relapsed or progressive KS, a phase II study of low-dose etoposide to assess its toxicity and efficacy was conducted...
  33. pmc More on HIV-associated Kaposi's sarcoma
    Susan E Krown
    N Engl J Med 358:535-6; author reply 536. 2008
  34. ncbi Editorial comment: reducing the risk of non-AIDS defining cancers
    Susan E Krown
    AIDS Read 18:30. 2008
  35. pmc Targeted therapy for Kaposi's sarcoma and Kaposi's sarcoma-associated herpesvirus
    Dirk P Dittmer
    Department of Microbiology and Immunology, Center for AIDS Research and Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    Curr Opin Oncol 19:452-7. 2007
    ..To summarize major recent findings on the biology of human herpesvirus-8, i.e. Kaposi's sarcoma-associated herpesvirus, and the implications of these findings for Kaposi's sarcoma treatment...
  36. ncbi Randomized phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi's sarcoma: an AIDS Malignancy Consortium Study
    Bruce J Dezube
    Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    J Clin Oncol 24:1389-94. 2006
    ..The aim of this trial was to extend these initial observations...
  37. ncbi Antitumor activity of oral 9-cis-retinoic acid in HIV-associated Kaposi's sarcoma
    Steven A Miles
    AIDS Malignancy Consortium Operations Center, University of Alabama at Birmingham, 2001 Third Avenue South, Room 1078, Birmingham, AL 35223, USA
    AIDS 16:421-9. 2002
    ..To assess the efficacy, safety and tolerance of oral 9-cis-retinoic acid in HIV-infected patients with Kaposi's sarcoma...
  38. ncbi Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study
    Mary Cianfrocca
    Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA
    J Clin Oncol 20:153-9. 2002
    ..Secondary aims were to evaluate tumor response, pharmacokinetics, and changes in blood levels of MMP-2, MMP-9, vascular endothelial growth factor (VEGF), and basic fibroblast growth factor (bFGF)...
  39. ncbi Breast cancer in the setting of HIV infection: cause for concern?
    Susan E Krown
    Cancer Invest 20:590-2. 2002
  40. ncbi Editorial comment: adjuvant radiotherapy for testicular cancer--balancing cancer treatment with HIV management
    Susan E Krown
    AIDS Read 14:190. 2004

Research Grants1

  1. AIDS ASSOCIATED MALIGNANCIES CLINICAL TRIALS CONSORTIUM
    Susan Krown; Fiscal Year: 2005
    ..In sum, our scientific and clinical resources make us uniquely positioned to continue to contribute to the collaborative clinical trials effort that has been developed in the AMC over the past 3 years. ..